We are live on ! Find out more
DGM

Darwin Global Management Portfolio holdings

AUM $3.77B
1-Year Est. Return 307.72%
This Fund
S&P 500
This Quarter Est. Return
+13.89%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$110M
AUM Growth
-$544M
Cap. Flow
-$556M
Cap. Flow %
-504.22%
Top 10 Hldgs %
100%
Holding
13
New
–
Increased
1
Reduced
–
Closed
12

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$68.9M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$455M
2
NTLA icon
Intellia Therapeutics
NTLA
+$71.6M
3
INBX
Inhibrx, Inc. Common Stock
INBX
+$25.9M
4
BNTX icon
BioNTech
BNTX
+$23.2M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AZN icon
1
AstraZeneca
AZN
$262B
$110M 100%
830,842
+574,888
+225% +$68.9M
ACRS icon
2
Aclaris Therapeutics
ACRS
$793M
– –
-216,143
Closed -$3.14M
BNTX icon
3
BioNTech
BNTX
$23.1B
– –
-90,057
Closed -$23.2M
ENTA icon
4
Enanta Pharmaceuticals
ENTA
$400M
– –
-166,190
Closed -$12.4M
FATE icon
5
Fate Therapeutics
FATE
$324M
– –
-153,537
Closed -$8.98M
FULC icon
6
Fulcrum Therapeutics
FULC
$243M
– –
-317,428
Closed -$5.62M
KROS icon
7
Keros Therapeutics
KROS
$211M
– –
-111,500
Closed -$6.52M
NTLA icon
8
Intellia Therapeutics
NTLA
$1.59B
– –
-605,587
Closed -$71.6M
PFE icon
9
Pfizer
PFE
$143B
– –
-7,697,762
Closed -$455M
VERV
10
DELISTED
Verve Therapeutics
VERV
– –
-23,104
Closed -$852K
VIR icon
11
Vir Biotechnology
VIR
$1.59B
– –
-145,841
Closed -$6.11M
CCXI
12
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-161,802
Closed -$5.89M
INBX
13
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-591,975
Closed -$25.9M

Similar funds

VVP
Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return
ABC
Associated Banc-Corp Green Bay, Wisconsin $3.78B AUM 21.74% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
VA
VestGen Advisors Inverness, Illinois $3.76B AUM 26.04% 1-Year Est. Return
GCC
Guardian Capital (Canada) Toronto, Ontario, Canada $3.78B AUM 33.04% 1-Year Est. Return
SB
SIG Brokerage New York $3.79B AUM 44.46% 1-Year Est. Return

Darwin Global Management's Q1 2022 Portfolio in Review

As of Q1 2022, Darwin Global Management held 13 positions worth $110M, down 83% from $655M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Darwin Global Management withdrew a net $556M in Q1 2022, closing 12 positions. Its most notable exit was Pfizer, an estimated $455M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Darwin Global Management added an estimated $68.9M to AstraZeneca.

  • Darwin Global Management added most to AstraZeneca in Q1 2022, an estimated $68.9M increase.
  • Darwin Global Management fully exited Pfizer in Q1 2022, selling an estimated $455M.
  • Darwin Global Management's ten largest holdings make up 100% of its $110M portfolio in Q1 2022.
  • Darwin Global Management opened 0 new positions and closed 12 in Q1 2022.
  • Darwin Global Management's portfolio value fell 83% quarter-over-quarter to $110M.

Based on Darwin Global Management's 13F filing for Q1 2022, filed 16 May 2022.